Category Archives: Chemistry

Browse > Home / Sports / OPINION: Chemistry leads UNT to day one advantage

Josh Friemel / Staff Writer –

As a society that demands honesty and the inside scoop from athletes, we question their team loyalty when they are blatantly honest about the team or their teammates.

On the flipside of that, we become restless when we hear the same “It was a great team effort” line from the exact same athlete.

That hasn’t been the case with Joe Dykstra this season.

Twice this year, Dykstra, head coach of the UNT swimming and diving team, has told me flat out that the Mean Green’s opponent will have the upper hand in a meet. The first time was against No. 6 ranked Texas A&M, a 186-105 loss.

The second time was two days before the Sun Belt Championships in Rockwall. Dykstra told me it was Denver’s meet to lose. That honesty may drive some people crazy.

But Dykstra doesn’t doubt his team at all. Even with what he calls the best team he’s ever had, pure talent isn’t the reason he thinks of his team so highly.

During his tenure at UNT, this team is his greatest because of its camaraderie. Of course, players like freshman Krista Rossum have helped, but team chemistry was his top reason.

It’s odd to have team chemistry in swimming, right? How can a sport with no ball have chemistry? Truth is, everyone has dealt with some sort of issue where good or bad chemistry has affected the outcome.

Chemistry isn’t just in sports. Everyone’s dealt with the kid who contributes absolutely nothing to a group project, thus dragging the group’s grade down.

However, it’s always very easy to tell when a team has really good chemistry.

What makes the swimming team’s chemistry more impressive is the number of new faces and underclassmen on the team. Of the 35 members, 21 are considered underclassmen, 14 of them freshmen. To be able to mesh so quickly with one another and to not have any senior-freshmen confrontations about team dominance is a moral victory in itself.

Thus far, Dykstra has been right. After the first day of championship action, the Mean Green is up on Denver 110-101 and sits at first place. The team also set two school records in the 800-free and 3-meter dive.

For at least one day, UNT’s chemistry is faring better than the team whose meet it was to lose. The Mean Green is outperforming expectations in Rockwall, and there’s no reason to think it won’t come out of the weekend as the SBC Champions.

Continued here:
OPINION: Chemistry leads UNT to day one advantage

NEW YORK, Feb. 21, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Rapid Tests and Point of Care Market to 2017 - Clinical Chemistry Tests to be the Major Revenue Generator

http://www.reportlinker.com/p0778001/Rapid-Tests-and-Point-of-Care-Market-to-2017---Clinical-Chemistry-Tests-to-be-the-Major-Revenue-Generator.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Rapid Tests and Point of Care Market to 2017 - Clinical Chemistry Tests to be the Major Revenue Generator

Summary

GBI Research's report, "Rapid Tests and Point of Care Market to 2017 - Clinical Chemistry Tests to be the Major Revenue Generator", provides key data, information and analysis on the global rapid tests and point of care (POC) market. The report provides information on the market landscape, the competitive landscape and market trend information on three rapid tests and POC market categories: clinical chemistry rapid tests and POC, immunochemistry rapid tests, and hematology rapid tests. The report provides comprehensive information on the key trends affecting these categories and key analytical content on the market's dynamics. The report also provides profiles of the major companies operating in the rapid tests and POC market and a detailed analysis of the pipeline products in each category. Furthermore, the report reviews the details of important merger and acquisition deals that have taken place in the rapid tests and POC market over the past four years. The report is compiled using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia and Brazil.

- The market size of three rapid tests and POC market categories - clinical chemistry rapid tests and POC, immunochemistry rapid tests, and hematology rapid tests.

- Annualized market revenue data from 2003 to 2010, forecast forward for 7 years to 2017.

- Qualitative analysis of key market trends, market drivers and restraints of each category within the rapid tests and POC market.

- The report also covers information on the leading players in the market and the leading technologies.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the global rapid tests and POC market.

- Design and develop your product's development, marketing and sales strategies.

- Exploit M&A opportunities by identifying market the players with the most innovative pipeline.

- Develop market entry and market expansion strategies.

- Identify the key players best positioned to take advantage of emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.

- What's the next big thing in the rapid tests and POC market landscape? Identify, understand and capitalize.

- Make more informed business decisions with the aid of insightful and in-depth analysis of the global rapid tests and POC market and the factors shaping it.

1 Table of Contents1 Table of Contents 31.1 List of Tables 61.2 List of Figures 72 Introduction 82.1 GBI Research Guidance 93 Global Rapid Tests and Point of Care Market - Market Characterization 103.1 Global Rapid Tests and Point of Care Market, Revenue ($m), 2003 - 2010 103.2 Global Rapid Tests and Point of Care Market, Revenue ($m), 2010 - 2017 113.3 Global Rapid Tests and Point of Care Market, Key Market Trends 123.3.1 Decentralization of Laboratories is a Growing Trend Across the World 123.3.2 Integration of POC Devices with Hospital Information Systems is a Growing Trend 123.4 Significant Consolidation in Recent Years to Reshape the Competitive Landscape of the Industry 133.4.1 Increased Demand for Rapid Tests and POC Testing in Emerging Countries Will Drive the Growth of the Market in the Near Future 133.5 Global Rapid Tests and Point of Care, Market Dynamics 143.5.1 Global Rapid Tests and Point of Care, Market Drivers 143.5.2 Global Rapid Tests and Point of Care, Market Restraints 164 Global Rapid Tests and Point of Care Market - Market Category Analysis and Forecasts 184.1 Clinical Chemistry Rapid Tests and POC 184.1.1 Clinical Chemistry Rapid Tests and POC Market, Global, Revenue ($m), 2003 - 2010 184.1.2 Clinical Chemistry Rapid Tests and POC Market, Global, Revenue Forecasts ($m), 2010 - 2017 204.2 Clinical Chemistry Rapid Tests and POC Market - Market Dynamics 214.2.1 Clinical Chemistry Rapid Tests and POC Market - Market Drivers 214.2.2 Clinical Chemistry Rapid Tests and POC Market - Market Restraints 224.3 Immunochemistry Rapid Tests Market 234.3.1 Immunochemistry Rapid Tests Market, Global, Revenue ($m), 2003 - 2010 234.3.2 Immunochemistry Rapid Tests Market, Global, Revenue Forecasts ($m), 2010 - 2017 244.4 Immunochemistry Rapid Tests Market - Market Dynamics 254.4.1 Immunochemistry Rapid Tests Market - Market Drivers 254.4.2 Immunochemistry Rapid Tests Market - Market Restraints 264.5 Hematology Rapid Tests Market 264.5.1 Hematology Rapid Tests Market, Global, Revenue ($m), 2003 - 2010 274.5.2 Hematology Rapid Tests Market, Global, Revenue Forecasts ($m), 2010 - 2017 284.6 Hematology Rapid Tests Market - Market Dynamics 294.6.1 Hematology Rapid Tests Market - Market Drivers 294.6.2 Hematology Rapid Tests Market - Market Restraints 305 Global Rapid Tests and Point of Care Market - Country Analysis and Forecasts 315.1 Rapid Tests and Point of Care Market - Cross - Country Analysis 315.2 Revenue Forecasts, by Country, 2003 - 2017 335.2.1 Rapid Tests and Point of Care Market, the US, Revenue ($m), 2003 - 2010 335.2.2 Rapid Tests and Point of Care Market, the US, Revenue ($m), 2010 - 2017 345.2.3 Rapid Tests and Point of Care Market, Canada, Revenue ($m), 2003 - 2010 355.2.4 Rapid Tests and Point of Care Market, Canada, Revenue ($m), 2010 - 2017 365.2.5 Rapid Tests and Point of Care Market, the UK, Revenue ($m), 2003 - 2010 375.2.6 Rapid Tests and Point of Care Market, the UK, Revenue ($m), 2010 - 2017 385.2.7 Rapid Tests and Point of Care Market, Germany, Revenue ($m), 2003 - 2010 395.2.8 Rapid Tests and Point of Care Market, Germany, Revenue ($m), 2010 - 2017 405.2.9 Rapid Tests and Point of Care Market, France, Revenue ($m), 2003 - 2010 415.2.10 Rapid Tests and Point of Care Market, France, Revenue ($m), 2010 - 2017 425.2.11 Rapid Tests and Point of Care Market, Italy, Revenue ($m), 2003 - 2010 435.2.12 Rapid Tests and Point of Care Market, Italy, Revenue ($m), 2010 - 2017 445.2.13 Rapid Tests and Point of Care Market, Spain, Revenue ($m), 2003 - 2010 455.2.14 Rapid Tests and Point of Care Market, Spain, Revenue ($m), 2010 - 2017 465.2.15 Rapid Tests and Point of Care Market, Japan, Revenue ($m), 2003 - 2010 475.2.16 Rapid Tests and Point of Care Market, Japan, Revenue ($m), 2010 - 2017 485.2.17 Rapid Tests and Point of Care Market, China, Revenue ($m), 2003 - 2010 495.2.18 Rapid Tests and Point of Care Market, China, Revenue ($m), 2010 - 2017 505.2.19 Rapid Tests and Point of Care Market, India, Revenue ($m), 2003 - 2010 515.2.20 Rapid Tests and Point of Care Market, India, Revenue ($m), 2010 - 2017 525.2.21 Rapid Tests and Point of Care Market, Australia, Revenue ($m), 2003 - 2010 535.2.22 Rapid Tests and Point of Care Market, Australia, Revenue ($m), 2010 - 2017 545.2.23 Rapid Tests and Point of Care Market, Brazil, Revenue ($m), 2003 - 2010 555.2.24 Rapid Tests and Point of Care Market, Brazil, Revenue ($m), 2010 - 2017 566 Global Rapid Tests and Point of Care Market - Key Market Participants 576.1 F. Hoffmann - La Roche Ltd. 576.1.1 Business Overview 576.1.2 Marketed Products 576.2 Abbott Laboratories 576.2.1 Business Overview 576.2.2 Marketed products 586.3 Siemens Healthcare (Subsidiary of Siemens AG) 586.3.1 Business Overview 586.3.2 Marketed Products 586.4 Beckman Coulter, Inc. (Subsidiary of Danaher Corporation) 596.4.1 Business Overview 596.4.2 Marketed Products: 596.5 bioMerieux S.A. (Subsidiary of Merieux Alliance Group) 606.5.1 Business Overview 606.5.2 Marketed products 606.6 DiaSorin S.p.A 606.6.1 Business Overview 606.6.2 Marketed Products: 617 Global Rapid Tests and Point of Care Market - Product Pipeline Analysis 627.1 Rapid Tests and Point of Care Market - Pipeline Product Summary 627.2 Rapid Tests and Point of Care Market - List of Pipeline Products 647.3 Rapid Tests and Point of Care - Profiles of Key Pipeline Products 667.3.1 ImmProCon Technology 667.3.2 RAPIDPoint 500 System - Lactate Assay 667.3.3 Sali - Chek Reader 667.3.4 Point Of Care Diagnostic Device 677.3.5 ACE Alera Clinical Chemistry System - Direct A1c Assay 677.3.6 Advia 120 Hematology System - IRF Test 677.3.7 Advia 2120 Hematology System - MPC Test 687.3.8 AIA - 600 II - D - dimer Test 688 Global Rapid Tests and Point of Care Market - Consolidation Landscape 698.1 Rapid Tests and Point of Care Market - Key Deals 2011 698.1.1 Sony Corporation of America Acquires Micronics 698.1.2 Roche Completes Acquisition of MTM Laboratories 698.1.3 Quest Diagnostics Completes Acquisition of Athena Diagnostics 698.1.4 Danaher Completes Acquisition of Beckman Coulter 708.2 Rapid Tests and Point of Care Market - Key Deals, 2007 - 2010 708.2.1 Merck Completes Acquisition of Millipore 708.2.2 Inverness Medical Innovations Acquires 78.13% Stake in Standard Diagnostics 718.2.3 Inverness Medical Innovations Completes Acquisition of Concateno from Marwyn 718.2.4 bioMerieux Acquires AviaraDx 718.2.5 Siemens Medical Acquires Dade Behring 718.2.6 Roche Acquires Ventana Medical Systems 728.2.7 Bio - Rad Laboratories Acquires Diamed 729 Appendix 739.1 Definitions 739.1.1 Clinical Chemistry Rapid Tests & POC 739.1.2 Immunochemistry Rapid Tests Market 739.1.3 Haematology Rapid Tests Market 739.2 Acronyms 739.3 Research Methodology 749.3.1 Secondary Research 749.3.2 Primary Research 749.3.3 Models 759.3.4 Forecasts 759.3.5 Expert Panels 759.4 Contact Us 759.5 Disclaimer 769.6 Sources 76

1.1 List of Tables

Table 1: Rapid Tests and Point of Care Market, Global, Revenue ($m), 2003 - 2010 10Table 2: Rapid Tests and Point of Care Market, Global, Revenue ($m), 2010 - 2017 11Table 3: Clinical Chemistry Rapid Tests and POC Market, Global, Revenue ($m), 2003 - 2010 19Table 4: Clinical Chemistry Rapid Tests and POC Market, Global, Revenue ($m), 2010 - 2017 20Table 5: Immunochemistry Rapid Tests Market, Global, Revenue ($m), 2003 - 2010 23Table 6: Immunochemistry Rapid Tests Market, Global, Revenue ($m), 2010 - 2017 24Table 7: Hematology Rapid Tests Market, Global, Revenue ($m), 2003 - 2010 27Table 8: Hematology Rapid Tests Market, Global, Revenue ($m), 2010 - 2017 28Table 9: Rapid Tests and Point of Care Market, Global, Cross Country Analysis, CAGR (%), 2003 - 2017 31Table 10: Rapid Tests and Point of Care Market, the US, Revenue ($m), 2003 - 2010 33Table 11: Rapid Tests and Point of Care Market, the US, Revenue ($m), 2010 - 2017 34Table 12: Rapid Tests and Point of Care Market, Canada, Revenue ($m), 2003 - 2010 35Table 13: Rapid Tests and Point of Care Market, Canada, Revenue ($m), 2010 - 2017 36Table 14: Rapid Tests and Point of Care Market, the UK, Revenue ($m), 2003 - 2010 37Table 15: Rapid Tests and Point of Care Market, the UK, Revenue ($m), 2010 - 2017 38Table 16: Rapid Tests and Point of Care Market, Germany, Revenue ($m), 2003 - 2010 39Table 17: Rapid Tests and Point of Care Market, the Germany, Revenue ($m), 2010 - 2017 40Table 18: Rapid Tests and Point of Care Market, France, Revenue ($m), 2003 - 2010 41Table 19: Rapid Tests and Point of Care Market, France, Revenue ($m), 2010 - 2017 42Table 20: Rapid Tests and Point of Care Market, Italy, Revenue ($m), 2003 - 2010 43Table 21: Rapid Tests and Point of Care Market, Italy, Revenue ($m), 2010 - 2017 44Table 22: Rapid Tests and Point of Care Market, Spain, Revenue ($m), 2003 - 2010 45Table 23: Rapid Tests and Point of Care Market, Spain, Revenue ($m), 2010 - 2017 46Table 24: Rapid Tests and Point of Care Market, Japan, Revenue ($m), 2003 - 2010 47Table 25: Rapid Tests and Point of Care Market, Japan, Revenue ($m), 2010 - 2017 48Table 26: Rapid Tests and Point of Care Market, China, Revenue ($m), 2003 - 2010 49Table 27: Rapid Tests and Point of Care Market, China, Revenue ($m), 2010 - 2017 50Table 28: Rapid Tests and Point of Care Market, India, Revenue ($m), 2003 - 2010 51Table 29: Rapid Tests and Point of Care Market, India, Revenue ($m), 2010 - 2017 52Table 30: Rapid Tests and Point of Care Market, Australia, Revenue ($m), 2003 - 2010 53Table 31: Rapid Tests and Point of Care Market, Australia, Revenue ($m), 2010 - 2017 54Table 32: Rapid Tests and Point of Care Market, Brazil, Revenue ($m), 2003-2010 55Table 33: Rapid Tests and Point of Care Market, Brazil, Revenue ($m), 2010 - 2017 56Table 34: Rapid Tests and Point of Care Market, Global, Pipeline Product Summary, 2010 62Table 35: Rapid Tests and Point of Care Market, Pipeline Assessment, by Development Stage 63Table 36: Rapid Tests and Point of Care Market, Global, List of Pipeline Products, 2010 - 2011 64Table 37: Rapid Test and Point of Care Market, Global, List of Pipeline Products, 2010 - 2012 65Table 38: ImmProCon Technology, Product Status, 2011 66Table 39: RAPIDPoint 500 System, Product Status, 2011 66Table 40: Sali - Chek Reader, Product Status, 2011 66Table 41: Point Of Care Diagnostic Device, Product Status, 2011 67Table 42: ACE Alera Clinical Chemistry System - Direct A1c Assay, Product Status, 2011 67Table 43: Advia 120 Hematology System - IRF (Immature Reticulocyte Fraction) Test, Product Status, 2011 67Table 44: Advia 2120 Hematology System - MPC (Mean Platelet Component) Test, Product Status, 2011 68Table 45: AIA (Automated Immunoassay Analyzer) - 600 II - D - dimer Test, Product Status, 2011 68

1.2 List of Figures

Figure 1: Rapid Tests and Point of Care Market, Global, Revenue ($m), 2003 - 2010 10Figure 2: Rapid Tests and Point of Care Market, Global, Revenue ($m), 2010 - 2017 11Figure 3: Rapid Tests and Point of Care Market, Market Categorization and Segmentation 18Figure 4: Clinical Chemistry Rapid Tests and POC Market, Global, Revenue ($m), 2003 - 2010 18Figure 5: Clinical Chemistry Rapid Tests and POC Market, Global, Revenue ($m), 2010 - 2017 20Figure 6: Immunochemistry Rapid Tests Market, Global, Revenue ($m), 2003 - 2010 23Figure 7: Immunochemistry Rapid Tests Market, Global, Revenue ($m), 2010 - 2017 24Figure 8: Hematology Rapid Tests Market, Global, Revenue ($m), 2003 - 2010 27Figure 9: Hematology Rapid Tests Market, Global, Revenue ($m), 2010 - 2017 28Figure 10: Rapid Tests and Point of Care Market, Global, Cross Country Analysis, CAGR (%), 2003 - 2017 31Figure 11: Rapid Tests and Point of Care Market, the US, Revenue ($m), 2003 - 2010 33Figure 12: Rapid Tests and Point of Care Market, the US, Revenue ($m), 2010 - 2017 34Figure 13: Rapid Tests and Point of Care Market, Canada, Revenue ($m), 2003 - 2010 35Figure 14: Rapid Tests and Point of Care Market, Canada, Revenue ($m), 2010 - 2017 36Figure 15: Rapid Tests and Point of Care Market, the UK, Revenue ($m), 2003 - 2010 37Figure 16: Rapid Tests and Point of Care Market, the UK, Revenue ($m), 2010 - 2017 38Figure 17: Rapid Tests and Point of Care Market, Germany, Revenue ($m), 2003 - 2010 39Figure 18: Rapid Tests and Point of Care Market, Germany, Revenue ($m), 2010 - 2017 40Figure 19: Rapid Tests and Point of Care Market, France, Revenue ($m), 2003 - 2010 41Figure 20: Rapid Tests and Point of Care Market, France, Revenue ($m), 2010 - 2017 42Figure 21: Rapid Tests and Point of Care Market, Italy, Revenue ($m), 2003 - 2010 43Figure 22: Rapid Tests and Point of Care Market, Italy, Revenue ($m), 2010 - 2017 44Figure 23: Rapid Tests and Point of Care Market, Spain, Revenue ($m), 2003 - 2010 45Figure 24: Rapid Tests and Point of Care Market, Spain, Revenue ($m), 2010 - 2017 46Figure 25: Rapid Tests and Point of Care Market, Japan, Revenue ($m), 2003 - 2010 47Figure 26: Rapid Tests and Point of Care Market, Japan, Revenue ($m), 2010 - 2017 48Figure 27: Rapid Tests and Point of Care Market, China, Revenue ($m), 2003 - 2010 49Figure 28: Rapid Tests and Point of Care Market, China, Revenue ($m), 2010 - 2017 50Figure 29: Rapid Tests and Point of Care Market, India, Revenue ($m), 2003 - 2010 51Figure 30: Rapid Tests and Point of Care Market, India, Revenue ($m), 2010 - 2017 52Figure 31: Rapid Tests and Point of Care Market, Australia, Revenue ($m), 2003 - 2010 53Figure 32: Rapid Tests and Point of Care Market, Australia, Revenue ($m), 2010 - 2017 54Figure 33: Rapid Tests and Point of Care Market, Brazil, Revenue ($m), 2003-2010 55Figure 34: Rapid Tests and Point of Care Market, Brazil, Revenue ($m), 2010 - 2017 56Figure 35: Rapid Tests and Point of Care Market, Global, Pipeline Product Summary (%), 2010 62Figure 36: Rapid Tests and Point of Care Market, Pipeline Assessment, by Development Stage 63

Companies mentioned

F. Hoffmann - La Roche Ltd.

Abbott Laboratories

Siemens Healthcare (Subsidiary of Siemens AG)

Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)

bioMerieux S.A. (Subsidiary of Merieux Alliance Group)

DiaSorin S.p.A

To order this report:In Vitro Diagnostic Industry: Rapid Tests and Point of Care Market to 2017 - Clinical Chemistry Tests to be the Major Revenue Generator

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

More here:
Rapid Tests and Point of Care Market to 2017 - Clinical Chemistry Tests to be the Major Revenue Generator

Spending nearly 10 days in the same hotels, on the same charter flights and facing the same opponents can either cause a losing team to come together or drift further apart. And for the Washington Wizards, the season’s longest — to this point — road trip through Detroit, Portland, Los Angeles, Utah and Phoenix went a long way toward helping the players establish more camaraderie as they shared meals, went to the movies and got more familiar with one another on a personal level.

“We’re most definitely better, chemistry-wise, being around each other off the court and playing hard for each other on the court,” Rashard Lewis said after the Wizards (7-25) finished 2-3 on the trip and doubled the number of road wins they had before leaving on Feb. 11. “It helps you come together on the court and play for each other instead of being selfish.”

The results were evident through the first two victories and even during some competitive stretches against the Clippers and the Suns. But the final dud of a second half in Phoenix proved that off-the-court chemistry doesn’t always translate to on-the-court success. The Suns buried the Wizards during a 31-6 run to close the third period, in an eight-minute stretch that Coach Randy Wittman described as “the most selfish spree of basketball since I’ve taken over.”

The Wizards had established a reputation as a one-on-one offensive team this season under former coach Flip Saunders, but Wittman had worked hard to make sure that his players trusted each other and relied on ball movement to get better, more efficient shots. The collapse during the 104-88 loss to Phoenix was more disturbing, because the Wizards had started the third period getting seven points by sharing the ball.

John Wall fed Nick Young for a jumper, then drove inside, drew Steve Nash and Jared Dudley, and fed Trevor Booker for vicious dunk in the lane. Booker then converted a three-point play that gave the Wizards a 55-54 lead with 8 minutes 13 seconds remaining in the period.

What followed was an incredible meltdown on both ends of the floor, a rapid descent that turned a close game into a laugher in a matter of minutes.

Wittman didn’t have to think too hard about what happened. “Selfish is what happened,” Wittman said. “We became selfish. We didn’t share the ball and tried to do everything one on one, and a good team like Phoenix is going to take that away from you. That’s all it was.”

The Wizards have had their share of second-half breakdowns, which is one of the reasons they have recorded 17 double-digit losses — second only to Charlotte — through the first half of this season. They will host Sacramento on Wednesday in the final game before the all-star break, which will probably feel like another road game considering how much the team has moved around.

Unlike last season, the Wizards are only slightly better at Verizon Center than they are away from home. They would like to head into the break on a positive note after failing to compete in Utah, where they trailed by 28 in the third quarter, and only showing up for 28 minutes in Phoenix, where they trailed by 26 in the fourth quarter. The Wizards lost each of the past three games by at least 14 points.

“It’s very disappointing,” Young said. “We’ve seen how good we can be. We could’ve made it a more positive road trip at 3-2 but to get blown out like that, it’s tough. But we’ve got to bounce back, look forward to Wednesday.”

The Wizards should also try to avoid having the kind of lengthy letdowns that have derailed them in recent losses to Houston and Miami, as they simply gave up or failed to play as a team.

As Nash and the Suns pounded them with crisp ball movement in the second half, the Wizards tried to respond with quick jumpers. Lewis was sitting next to Maurice Evans as the Suns scored 16 consecutive points, with Nash ending the run with a difficult, hanging jumper over Wall to put his team ahead, 70-55.

Evans mentioned that the game was getting out of control and Lewis looked up, stunned at how the team could go from leading to trailing by so much so quickly.

“It flashed before my eyes. It happened so fast. I couldn’t believe it,” Lewis said. “It’s disappointing, because we wanted to win this one. We felt it would’ve been a successful trip even though we didn’t play well in Utah. I still think we did a lot of positive things.”

After the loss to Phoenix, Jordan Crawford didn’t dispute Wittman’s notion that the team played selfishly.

“Yeah, probably. When you get down, everybody try to be the hero. I think that cost us,” said Crawford, who attempted a pull-up three-pointer on a three-on-two fast break during the run. He added that the Wizards did make some positive strides on the trip. “We’ve shown that even on the road, we can beat good teams. Good teams do it every night. I think we went out and played hard. We just had some mental lapses.”

Continued here:
Washington Wizards building better chemistry but still regress into selfish play

The technology that Google uses to analyze trillions of Web pages is being brought to bear on the way molecules are shaped and organized. Aurora Clark, an associate professor of chemistry at Washington State University, has adapted Google's PageRank software to create moleculaRnetworks, which scientists can use to determine molecular shapes and chemical reactions without the expense, logistics and occasional danger of lab experiments.

"What's most cool about this work is we can take technology from a totally separate realm of science, computer science, and apply it to understanding our natural world," says Clark.

Clark and colleagues from the University of Arizona discuss the software in a recent online article in The Journal of Computational Chemistry. Their work is funded by the U.S. Department of Energy's Basic Energy Sciences program.

The software focuses on hydrogen bonds in water, earth's most abundant solvent and a major player in most every biological process. "From a biological or chemical standpoint, water is where it's at," says Clark.

In living things, water can perform key functions like helping proteins fold or organizing itself around the things it dissolves so molecules stay apart in a fluid state. But the processes are dazzlingly complex, changing in fractions of a second and in myriad possible forms.

Much like the trillion-plus Web domains on the Internet.

Google's PageRank software, developed by its founders at Stanford University, uses an algorithm-a set of mathematical formulas-to measure and prioritize the relevance of various Web pages to a user's search.

Clark and her colleagues realized that the interactions between molecules are a lot like links between Web pages. Some links between some molecules will be stronger and more likely than others.

"So the same algorithm that is used to understand how Web pages are connected can be used to understand how molecules interact," says Clark.

The PageRank algorithm is particularly efficient because it can look at a massive amount of the Web at once. Similarly, it can quickly characterize the interactions of millions of molecules and help researchers predict how various chemicals will react with one another.

Ultimately, researchers can use the software to design drugs, investigate the roles of misfolded proteins in disease and analyze radioactive pollutants, Clark says.

"Computational chemistry is becoming the third leg in the stool of chemistry," the other two being experimental and analytical chemistry, says Clark. "You can call it the ultimate green chemistry. We don't produce any waste. No one gets exposed to anything harmful."

Clark, who uses Pacific Northwest National Laboratories supercomputers and a computer cluster on WSU's Pullman campus, specializes in the remediation and separation of radioactive materials. With computational chemistry and her Google-based software, she says, she "can learn about all those really nasty things without ever touching them."

Excerpt from:
Google Algorithm Helps Drive Computational Chemistry With moleculaRnetworks

Jeremy Lin flirted with a triple double but the New York Knicks struggled to find the right chemistry with the return of Carmelo Anthony, losing 100-92 to the New Jersey Nets on Monday.

"I need to come out with more energy and the team needs to come out with more energy. That is why we lost," said Lin. "We are not in panic mode. We are going to have to work through some struggles but as long as we are all committed and buy in, we will be fine."

It marked just the second loss since Lin's amazing run began February 4 against the Nets when he blitzed New Jersey's defence for 25 points.

The Knicks have eight wins and two losses since the NBA legend of Lin was born with that 99-92 win over the Nets.

Lin finished with a team-high 21 points, nine assists and seven rebounds as all five Knicks starters reached double figures in scoring in Monday's loss.

"Jeremy still got 21 and nine and he still had a great game, a good game," said Knicks coach Mike D'Antoni. "Our energy wasn't right the whole night. We got some sorting out to do."

Lin's incredible season began when the former benchwarmer was called up with two starters missing and answered with the most points of any NBA player in his first five starts since the NBA and ABA merged in 1976.

The fairy-tale rise of Lin, the first American-born NBA player of Taiwanese and Chinese heritage, is all the more remarkable considering he was cut by two clubs before joining the Knicks.

But the Knicks had no answer on Monday to Nets point guard Deron Williams who finished with a season-high 38 points.

Williams also scored a career-high eight three-pointers for the Nets who snapped a five-game losing streak to the Knicks.

Kris Humphries had a double-double with 14 points and 14 rebounds for New Jersey.

The Knicks welcomed superstar Anthony back into the lineup from injury Monday but he struggled to find a role in their revamped offence.

Anthony shot just four-of-11 from the field and had 11 points, well below his season average of 22.3.

Anthony had missed the team's last seven games with a groin strain and point guard Baron Davis also made his season debut against the Nets.

But D'Antoni refused to single out a player for blame, instead insisting the whole team was at fault for the loss.

"When a guy comes back others guys stand around and watch what he is doing," D'Antoni said. "It was the whole team's fault.

"Two or three guys were new in there and we weren't rolling."

Amare Stoudemire (17), Tyson Chandler (14) and Landry Fields (10) also reached double figures for the Knicks.

D'Antoni said they hope to use the upcoming All-Star break to better identify the role of each player on the team.

"We got some things to sort out and figure out what identity we have to have. We need to retool a little bit and see what we can do."

Lin has been running the Knicks' offence since Anthony got hurt. Lin believes the two will eventually find their roles under D'Antoni's system.

"We both make plays and we need to find a good balance," said Lin who makes $17 million a season less than Anthony.

"It is tough right now with no practice time and then you throw in J.R. Smith and Baron Davis. There will be an adjustment time and things to talk about."

Lin said it is frustrating to beat the defending champion Dallas Mavericks one night then lose to a last-place team the next.

"This is definitely a gut check," Lin said. "We have to look inside ourselves and come with the same energy and passion against teams with poorer records than the defending champions or the Los Angeles Lakers."

See original here:
Lin's Knicks fail to find chemistry in loss to Nets

Quotes delayed, except where indicated otherwise. Delay times are 15 mins for NASDAQ, NYSE and Amex. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.

Fundamental company data provided by Capital IQ. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data and daily updates provided by Morningstar, Inc.

Yahoo! - ABC News Network

Read more from the original source:
Research and Markets: Organic Chemistry I as a Second Language: First Semester Topics, 3rd Edition Will Assist You to ...